The CLPTM1 (Cleft Lip and Palate Transmembrane Protein 1) antibody is a tool used to study the CLPTM1 protein, which is encoded by the *CLPTM1* gene located on human chromosome 19q13.3. Initially identified for its potential role in craniofacial development, CLPTM1 has gained attention for its involvement in cancer biology, particularly in cisplatin resistance and tumorigenesis. CLPTM1 is a transmembrane protein implicated in regulating apoptosis, autophagy, and intracellular vesicle trafficking. Studies suggest it interacts with components of the Bcl-2 family and modulates mitochondrial pathways, influencing cell survival under stress conditions. Overexpression of CLPTM1 has been observed in various cancers, including lung, ovarian, and oral squamous cell carcinomas, where it correlates with poor prognosis and chemoresistance. The CLPTM1 antibody is primarily utilized in research applications such as Western blotting, immunohistochemistry, and immunofluorescence to detect protein expression, localization, and interactions. Its development has facilitated investigations into CLPTM1's mechanistic roles in cancer progression and therapy resistance, offering potential as a biomarker or therapeutic target. However, the exact molecular functions of CLPTM1 remain partially understood, necessitating further studies to clarify its regulatory networks and clinical relevance.